Double-Barreled immune attack aims to wipe out T-ALL
NCT ID NCT05277753
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a two-part immune therapy for people with T-cell acute lymphoblastic leukemia (T-ALL). First, patients receive specially engineered T cells (CAR-T) that target multiple markers on leukemia cells. Then, they get a booster with cytotoxic T cells and a dendritic cell vaccine to strengthen the immune response. The goal is to eliminate even tiny traces of leukemia, potentially leading to long-term remission.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Antigen-specific T cells (CAR-T/CTL) and dendritic cell vaccine (DCvac)
- What this could lead to
- If successful, this combination therapy could achieve deep remission in T-ALL patients, potentially reducing relapse risk and pointing toward long-term disease control without further treatment.
- What could go wrong
- This is a very early Phase 1 trial with only 10 participants, so safety and effectiveness are not yet proven. The therapy involves complex cell engineering, and there is a risk of serious side effects or the treatment not working as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Personalized chemo dosing may boost survival in kids with High-Risk leukemia
- Engineered immune cells take aim at Hard-to-Treat T-Cell cancers
- Engineered immune cells take aim at stubborn blood cancers
- Chemotherapy showdown: which combo works best for T-Cell cancers in kids?
- Gene test spots hidden leukemia in kids
- Exercise during chemo: new study tests strength training for children with leukemia